Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
May 03, 2024 16:30 ET
|
Fate Therapeutics, Inc.
Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Technology Incorporated into FT522 Induces Functional Persistence and...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 16:01 ET
|
NewAmsterdam Pharma N.V.
NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 16:00 ET
|
Mural Oncology, Inc.
WALTHAM, Mass and DUBLIN, May 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and...
Low-Dose Naltrexone in Gastroenterology: A Bonafide ‘Wonder Drug’
May 03, 2024 14:31 ET
|
GI Alliance
St. Louis, MO, May 03, 2024 (GLOBE NEWSWIRE) -- Dr. Leonard Weinstock, a leading gastroenterologist, delves into the promising realm of low-dose naltrexone (LDN) in his recent byline article. Dr....
Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100 percent biochemical free recurrence rate more than two years post-surgery
May 03, 2024 12:39 ET
|
Janssen Cilag International NV
Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate cancer (HRLPC) experience disease recurrence...
Women’s health in Calgary gets multi-year boost thanks to $10M investment through Calgary Health Foundation
May 03, 2024 12:00 ET
|
Calgary Health Foundation
Calgary, Alberta, Canada, May 03, 2024 (GLOBE NEWSWIRE) -- Calgary Health Foundation announces a $10M investment over two years from the Government of Alberta in support of women’s health...
TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
May 03, 2024 11:53 ET
|
Janssen Cilag International NV
New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98 percent achieving a CR within 12 weeks1 TAR-200 provides durable CRs in patients with Bacillus...
Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer
May 03, 2024 11:32 ET
|
The Wistar Institute
PHILADELPHIA, PA, May 03, 2024 (GLOBE NEWSWIRE) -- The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma — a serious and often...
Market for Functional Food Ingredients Industry is Booming on Health and Wellness Trends
May 03, 2024 09:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, May 03, 2024 (GLOBE NEWSWIRE) -- Functional food ingredients are bioactive compounds that are added to food or beverages to promote health benefits beyond basic nutrition. These ingredients...
Getting the Math Right: The Growing Movement to Improve How Medicines Are Valued Will Take Center Stage at ISPOR 2024
May 03, 2024 09:00 ET
|
No Patient Left Behind
ATLANTA, May 03, 2024 (GLOBE NEWSWIRE) -- Leading health economists will gather in Atlanta on May 5-8 for a meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR),...